Copyright (c) 2009 Yahoo! Inc. All rights reserved.http://finance.yahoo.com/q/h?s=oncyLatest Financial News for Oncolytics Biotech, Inc.en-usTue, 22 Dec 2009 16:43:08 Etc/GMThttp://us.news2.yimg.com/us.yimg.com/p/fi/pr/40197.gifhttp://finance.yahoo.com14417http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/q/ud?s=ONCYyahoo_finance/1736915582Tue, 22 Dec 2009 16:43:08 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091211/to582.html?.v=14Oncolytics Biotech Inc. today announced the appointment of Dr. Alan Warrander to the role of Senior Vice President, Global Licensing and Business Development.yahoo_finance/1833729941Fri, 11 Dec 2009 12:30:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091202/to313.html?.v=7Oncolytics Biotech Inc. announced today that in connection with its previously announced unit offering, the underwriters have exercised in full their over-allotment option and purchased an additional 637,500 units.yahoo_finance/2676563821Wed, 2 Dec 2009 14:35:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/cnw/091202/oncolytics_over_allot.html?.v=2yahoo_finance/397389912Wed, 2 Dec 2009 14:35:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091123/to853.html?.v=8Oncolytics Biotech Inc. announced today that it has closed its previously announced US$12,750,000 offering in which a syndicate of underwriters purchased 4,250,000 units of the Company, each unit comprised of one common share and 0.4 of a common share purchase warrant, at a price of US$3.00 per unit.yahoo_finance/4080674109Mon, 23 Nov 2009 14:19:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/cnw/091123/oncolytics_us_12_75_m.html?.v=1yahoo_finance/3625039561Mon, 23 Nov 2009 14:19:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091118/to766.html?.v=12Oncolytics Biotech Inc. announced today that it has entered into an underwriting agreement for an offering of 4,250,000 units, each comprised of one common share and 0.4 of a common share purchase warrant, at a price of US$3.00 per unit to raise gross proceeds of US$12,750,000.yahoo_finance/170780125Wed, 18 Nov 2009 14:31:00 Etc/GMThttp://us.rd.yahoo.com/finance/external/tsmfe/rss/SIG=12s5lmcno/*http%3A//www.thestreet.com/_yahoo/story/10628304/1/poniard-netlist-early-volume-plays.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NAyahoo_finance/3708558768Wed, 18 Nov 2009 13:57:19 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091117/to741.html?.v=15Oncolytics Biotech Inc. announced today that it is undertaking an overnight marketed offering of units, each comprised of one common share and a portion of a common share purchase warrant to be effected in each of the Canadian provinces of British Columbia, Alberta, Manitoba and Ontario by way of a prospectus supplement to Oncolytics' base shelf short form prospectus, and in the United States pursuant to a prospectus supplement to the Oncolytics' Form F-10 registration statement as filed with the United States Securities and Exchange Commission on June 6, 2008, as amended on June 17, 2008, pursuant to the United States Securities Act of 1933, as amended.yahoo_finance/998967300Tue, 17 Nov 2009 22:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091117/to713.html?.v=3Oncolytics Biotech Inc. today announced updated results from a Phase I/II U.K. trial of REOLYSIN® combined with paclitaxel/carboplatin for patients with advanced cancers in a poster presentation at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference being held in Boston, Massachusetts.yahoo_finance/3368820936Tue, 17 Nov 2009 13:30:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091116/to661.html?.v=10Oncolytics Biotech Inc. today announced that a poster presentation covering updated results of a Phase I/II U.K. trial of REOLYSIN® combined with paclitaxel/carboplatin for patients with advanced cancers will be presented on November 17, 2009 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference being held in Boston, Massachusetts.yahoo_finance/890004283Mon, 16 Nov 2009 12:30:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/a/r/o/oncy.htmlyahoo_finance/3507434047Sun, 8 Nov 2009 14:19:54 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091106/to440.html?.v=56Oncolytics Biotech Inc. today announced updated results from a Phase II study of intravenous REOLYSIN® in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th.yahoo_finance/848262507Fri, 6 Nov 2009 14:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091105/to404.html?.v=60Oncolytics Biotech Inc. today announced its financial results for the three and nine-month periods ended September 30, 2009.yahoo_finance/3564078501Thu, 5 Nov 2009 12:30:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091103/to334.html?.v=4Oncolytics Biotech Inc. announces, that pursuant to the accelerated expiry of those warrants issued on May 13, 2009, the Corporation has received proceeds of approximately $9.1 million resulting from the exercise of all 3,795,000 warrants.yahoo_finance/1715437689Tue, 3 Nov 2009 12:30:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091102/to278.html?.v=85Dr. Matt Coffey, Chief Operating Officer of Oncolytics Biotech Inc. , will present a corporate overview of the Company at the BIO-Europe 2009 15th Annual International Partnering Conference on Wednesday, November 4, 2009.yahoo_finance/998332354Mon, 2 Nov 2009 12:30:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091030/to257.html?.v=12Oncolytics Biotech Inc. announced that a poster presentation covering updated results of a Phase II study of REOLYSIN® administered intravenously to patients with sarcomas metastatic to the lung will be presented at the 15th Annual Connective Tissue Oncology Society Meeting being held in Miami Beach, Florida on November 6th, 2009.yahoo_finance/3418551359Fri, 30 Oct 2009 11:30:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091027/to941.html?.v=6Oncolytics Biotech Inc. today announced that it has been granted its 33rd U.S. Patent, # 7,608,257, entitled "Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus."yahoo_finance/2438483578Tue, 27 Oct 2009 11:30:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091026/to903.html?.v=4Oncolytics Biotech Inc. announces, that pursuant to the provision of written notification on September 23, 2009, of the accelerated expiry of those warrants issued on December 5, 2008, and those warrants amended December 18, 2008, the Corporation has received proceeds of approximately $5.8 million resulting from the exercise of all 3,235,000 warrants.yahoo_finance/739409751Mon, 26 Oct 2009 11:30:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/prnews/091023/to888.html?.v=6Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. , will present a corporate overview of the Company at the 8th Annual BIO Investor Forum 2009 on Wednesday, October 28, 2009 at 3:00 p.m.yahoo_finance/3234682866Fri, 23 Oct 2009 16:19:00 Etc/GMT